Skip to main content
Defiance International

Published study records

Study records for MOTS-c

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

241 study records.

30 evidence-verified · 160 citation-verified · 43 identifier-confirmed · 8 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 39
  • In vivo/preclinical: 71
  • Review/meta-analysis: 23
  • Other: 0
Filter study recordsReset filters

Current study records

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2025

Diagnostic relevance of Humanin, GAS5 and miR-21/miR-103 in prostate disease risk stratification.

Clinical and experimental medicine · 2025

Study scale: We studied a cohort of 375 male patients with clinical suspicion of prostate cancer (PCa), enrolled at the Urology Clinic of the University Hospital of Sassari.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

We studied a cohort of 375 male patients with clinical suspicion of prostate cancer (PCa), enrolled at the Urology Clinic of the University Hospital of Sassari.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2024

Mitochondria-derived peptide is an effective target for treating streptozotocin induced painful diabetic neuropathy through induction of activated protein kinase/peroxisome proliferator-activated receptor gamma coactivator 1alpha -mediated mitochondrial biogenesis.

Molecular pain · 2024

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

The mechanical pain threshold of mice was measured by von Frey monofilaments (Bio-VF-M, Bioseb, USA) with the up-down method.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Human research · Verification: Evidence verified by machine against declared source

  • 2023

Evaluation of Coronary Flow Level with Mots-C in Patients with STEMI Undergoing Primary PCI.

Arquivos brasileiros de cardiologia · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

We aimed to investigate the role of MOTS-C, which is known to have cytoprotective properties in the pathogenesis of the no-reflow phenomenon, by comparing the coronary flow rate and MOTS-C levels in patients with STEMI submitted to primary PCI.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2023

The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy.

Acta biochimica et biophysica Sinica · 2023

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Public plain-language summary

Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not reported in the declared source.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

The lysate was centrifuged, the supernatant was collected, and the protein concentration was measured with a BCA kit (23225; Thermo Scientific, Waltham, USA).

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: Narrative review · Verification: Evidence verified by machine against declared source

  • 2020

Mechanisms of protection of retinal pigment epithelial cells from oxidant injury by humanin and other mitochondrial-derived peptides: Implications for age-related macular degeneration.

Redox biology · 2020

Study scale: Not reported in the declared source.

Abstract only: Open source record

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Not reported in the declared source.

Study design

Not reported in the declared source.

Participants or experimental system

Not reported in the declared source.

Study scale

Not reported in the declared source.

Intervention or exposure

Not reported in the declared source.

Comparator

Not reported in the declared source.

Outcomes examined

Not reported in the declared source.

Limitations and uncertainty

Not reported in the declared source.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Summary: exact sentences from the abstract. Checked

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2026

MOTS‐c protects against placental injury via Nrf2 activation in hypoxia‐induced intrauterine growth restriction mice.

International journal of molecular medicine · 2026

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2026

Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor.

Molecular neurobiology · 2026

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2025

MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.

Redox biology · 2025

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Evidence verified by machine against declared source

  • 2025

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.

Experimental & molecular medicine · 2025

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2025

Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.

Frontiers in physiology · 2025

Study scale: Not published. Nothing is shown here and nothing is substituted for it.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Study design

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Study scale

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Comparator

Not published. Nothing is shown here and nothing is substituted for it.

Outcomes examined

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2025

Characterization of the Avian Mitochondrial-Derived Peptide MOTS-c and Its Potential Role as a Metabolic Regulator.

Animals : an open access journal from MDPI · 2025

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Research question

Not published. Nothing is shown here and nothing is substituted for it.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source

  • 2025

MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3.

Scientific reports · 2025

Study scale: Not reported in the declared source.

Abstract only: Open source record

Summary withheld

No summary text is published for this record. This does not change the record’s verification.

Participants or experimental system

Not published. Nothing is shown here and nothing is substituted for it.

Intervention or exposure

Not published. Nothing is shown here and nothing is substituted for it.

Limitations and uncertainty

Not published. Nothing is shown here and nothing is substituted for it.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.